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CLINICAL INVESTIGATIONS
Analysis of Episodes of Care in Medicare Beneficiaries Newly
Diagnosed with Alzheimer’s Disease
Rezaul K. Khandker, PhD,* Christopher M. Black, MPH,* Lin Xie, MS,†
M. Furaha Kariburyo, MPH,† Baishali M. Ambegaonkar, PhD,* Onur Baser, PhD,‡
Huseyin Yuce, PhD,§ and Howard Fillit, MD¶k
OBJECTIVES: To study transitions between healthcare
settings and quantify the cost burdens associated with dif-
ferent combinations of transitions during a 6-month
period before initial Alzheimer’s disease (AD) diagnosis so
as to investigate how using an episode-of-care approach to
payment for specific disease states might apply in AD.
DESIGN: A retrospective observational cohort study.
SETTING: United States.
PARTICIPANTS: A random sample of 8,995 individuals
aged 65 to 100 with a diagnosis of AD (International Clas-
sification of Diseases, Ninth Revision, Clinical Modification
code 331.0) were identified from the Medicare database
between January 1, 2011, and June 30, 2014. This analysis
identified individuals with AD diagnosed in inpatient
(18%), skilled nursing facility (SNF) (1%), hospice (4%),
and home and outpatient (77%) settings and analyzed epi-
sodes that began in the index setting (defined as the care set-
ting in which the individual was first diagnosed with AD).
MEASUREMENTS: Study outcomes included number of
transitions between settings, primary discharge diagnoses,
and total all-cause healthcare costs during the 6 months
after the AD diagnosis.
RESULTS: The average numbers of transitions between
care settings were 2.8 originating from an inpatient set-
ting, 2.4 from a SNF, 0.3 from a hospice setting and 0.7
from a home or outpatient setting during 6 months post-
AD diagnosis. The overall cost burden during the 6
months after AD diagnosis (including costs incurred at the
index setting) was high for individuals diagnosed in a
nonambulatory setting (mean $41,468). Individuals diag-
nosed in an ambulatory setting incurred only $12,597 in
costs during the same period.
CONCLUSION: Episodes of care can be defined and stud-
ied in individuals with AD. An episode-of-care approach
to payment could encourage providers to use the contin-
uum of care needed for quality medical management in
AD more efficiently. J Am Geriatr Soc 66:864–870, 2018.
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In the current U.S. healthcare environment, policy-makers are searching for alternative payment models to
improve quality of care, promote efficiency, and reduce
healthcare spending.1,2 Episode-based payment, also
known as bundled payments, are payment models
designed to pay a single price for all services that a person
needs during an entire episode of care. The goal is to pro-
vide incentives to healthcare providers to reduce unneces-
sary services within each episode of care by providing
better care at lower costs.3 To our knowledge, no studies
have evaluated episode-based payment methods associated
with Alzheimer’s disease (AD). An estimated 5.4 million
individuals in the United States are currently diagnosed
with AD, with approximately 5 million of them being
aged 65 and older.4 More than 15 million family members
and other unpaid caregivers provided an estimated 18 bil-
lion hours of care to people with AD and other dementias,
a contribution valued at more than $217 billion in 2014.
In 2016, total healthcare costs, including long-term care
and hospice, for people with dementia were estimated to
be approximately $236 billion, with a steady increase
from 2013 to 2016.5–8 One way to understand and ana-
lyze the longitudinal healthcare cost of AD is to categorize
these costs into distinct episodes of care. An episode of
care can be defined as a series of temporally contiguous
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healthcare services related to the treatment of a disease
through interactions between individuals with the disease
and providers.9,10
This study analyzed episodes of care for Medicare
beneficiaries newly diagnosed with AD. The purpose was
to describe transitions between healthcare settings and to
examine and quantify the cost associated with different
combinations of transitions during the 6 months after ini-
tial AD diagnosis. An objective of this study was to
explore, using an episode-of-care approach, whether novel
methods of payment for dementia care might be possible
as a way to promote better quality of care.
METHODS
Data Source
A retrospective analysis was performed of individuals
newly diagnosed with AD using the Medicare 5% national
sample administrative database from January 2010
through December 2014. Medicare claims data files used
in this study included inpatient and outpatient, Medicare
carrier, Part D drug events, skilled nursing facility (SNF),
home health agency (HHA), hospice, durable medical
equipment (DME), and Medicare denominator file, which
contains demographic and enrollment information of
Medicare beneficiaries.
Participant Identification
Beneficiaries aged 65 to 100 and diagnosed with 1 pri-
mary or 2 or more secondary diagnoses for AD (Interna-
tional Classification of Diseases, Ninth Edition, Clinical
Modification (ICD-9-CM) code 331.0) during the identifi-
cation period (January 1, 2011–June 30, 2014) were
included in the study. The first AD diagnosis date was des-
ignated as the index date. Participants were also required
to have continuous health plan enrollment with medical
and pharmacy benefits for at least 12 months before (base-
line period) and 6 months after (follow-up period) the
index date. Individuals with pharmacy claims for an anti-
dementia drug (donepezil, rivastigmine, galantamine,
memantine) or claims of AD or AD-related dementia
(ICD-9-CM codes 290.xx, 294.xx, 331.1, 331.2, 331.7,
331.82, 331.89, 331.9, 797) during the baseline period
were excluded. This analysis identified individuals diag-
nosed in inpatient, SNF, hospice, and home or outpatient
settings. Home and outpatient settings included outpatient,
DME, HHA, and Medicare Carrier outpatient settings.
Episode-of-Care Measurement
This retrospective study was two faceted. The first facet
was to examine transitions between settings and overall
cost burden during the 6 months after AD diagnosis in
individuals newly diagnosed with AD in inpatient, SNF,
hospice, and home and outpatient settings. The second
facet was to examine and quantify cost burden associated
with common combinations and to evaluate admitting
diagnoses. We analyzed episodes that began in the setting
where AD was first diagnosed and then studied participant
pathways and transitions of care between settings for up
to 3 transitions during the 6 months after the AD diagno-
sis. All transitions between settings for each participant
were then collated into one “combination”. This analysis
focused on the 4 most commonly observed combinations
in our study sample.
Outcomes Variables
Study outcomes included the number of transitions
between settings, total all-cause healthcare costs, and costs
for the first 3 transitions during the 6 months after AD
diagnosis. Total costs were censored at 6 months. For the
4 most frequent combinations of transition, we analyzed
length of stay (LOS), primary diagnoses, and healthcare
costs of the first 3 settings in the combination. The dis-
charge diagnoses coded on inpatient, SNF, and hospice
claims were captured. The principal diagnosis coded on an
outpatient claim was used as the primary diagnosis in an
outpatient setting.
Baseline Variables
Baseline characteristics from 12 months before an AD
diagnosis (age, race, sex, U.S. geographical region, individ-
ual comorbid conditions) were evaluated.
Statistical Analysis
All study variables were examined descriptively. Numbers
and percentages were determined for dichotomous and
polychotomous variables. Means and standard deviations
were determined for continuous variables.
RESULTS
Participant Characteristics
After applying the study selection criteria, 8,995 individu-
als newly diagnosed with AD aged 65 to 100 were selected
for analysis: 18% in inpatient settings, 77% in home
and outpatient settings, 1% in SNFs, and 4% in hospice
(Supplementary Figure S1).
The overall mean age was 84, 82% of participants
were white, 77% were female, 37% resided in the South
at the time of diagnosis. The most common comorbidities
were hypertension (55%), diabetes (26%), chronic pulmo-
nary disease (19%), cerebrovascular disease (18%), and
mood disorder (16%) (Supplementary Table S1).
Transitions of Care Between Settings
Inpatient
During the 6 months after AD diagnosis, the average num-
ber of transitions was 2.8 for 1,637 individuals with AD
diagnosed in the inpatient setting (18%). Approximately
half of the individuals diagnosed in inpatient settings tran-
sitioned to a SNF and 49% to home and outpatient set-
tings. Of those who transitioned to a SNF, approximately
14% were readmitted to the hospital, and 78% were
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discharged home. Of those who were discharged to home
or an outpatient setting, 58% did not have a second tran-
sition, and almost 37% were re-hospitalized. The 30-day
hospital readmission rate after index hospitalization dis-
charge was 22%. Participants who remained in the home
or outpatient setting and did not have a second transition
had almost $30,000 lower costs than those who were
readmitted to the hospital (Figure 2a).
Home and outpatient
Most individuals newly diagnosed with AD were diag-
nosed in the home or outpatient setting (n56,912) and
had an average of 0.7 transitions between care settings
during the 6 months after AD diagnosis. Of participants
diagnosed in home and outpatient settings, 76.5%
remained in the original setting and did not transition to
another care setting, and 19.6% were later admitted to
the hospital during the 6 months after AD diagnosis. The
cost of care was $46,941 more for participants who had a
second transition from inpatient to SNF than for those
who remained in the home or outpatient setting and
$24,308 more for those who had a second transition from
inpatient to home or outpatient (Figure 2b).
Skilled Nursing Facility
Participants who were initially diagnosed in a SNF (n592)
had an average of 2.4 transitions between care settings
over the 6 months after AD diagnosis. Seventy-seven per-
cent of participants diagnosed in a SNF were discharged
to a home or outpatient setting, and 18.5% were admitted
to the hospital (Figure 3a).
Hospice
The mean number of transitions between care settings was
0.3 for participants originally diagnosed with AD in a
hospice setting (n5354). More than three-quarters of these
participants remained in hospice and did not transition to
another setting during the 6 months after AD diagnosis.
Total Medicare expenditures were $30,169 for those who
did not transition to another setting during the 6 months
after AD diagnosis and $46,223 for those who had their
first transition to an inpatient setting and then to a SNF
(Figure 3b).
Primary Discharge Diagnoses Associated with
Commonly Observed Combinations of Transitions
Four commonly observed combinations of transitions were
further evaluated.
Home or Outpatient Setting fiInpatient Settingfi Home or
Outpatient Setting
The first combinations included 765 participants who
transitioned from home or outpatient to inpatient and
back to home or outpatient setting. The primary diagnoses
were AD for index home or outpatient, malaise or fatigue
for inpatient setting, and diabetes for second home or out-
patient settings (Supplementary Figure S1).
Inpatient Setting fiSNF Settingfi Home or Outpatient
Setting
The second combination included 646 participants who
went from inpatient to SNF then home or outpatient set-
ting. The first primary discharge diagnosis in the index
inpatient setting was malaise or fatigue. AD was not
recorded in the top 9 primary discharge diagnoses in the
inpatient setting. AD was the principal discharge diagnosis
in the SNF setting, and hypertension was the primary
diagnosis for participants in the home or outpatient setting
(Supplementary Figure S2).
Figure 1. Flow chart for participant selection criteria.
866 KHANDKER ET AL. MAY 2018–VOL. 66, NO. 5 JAGS
Home or Outpatient Setting fiInpatient Settingfi SNF
Setting
Participants who transitioned from home or outpatient to
inpatient and then SNF setting were captured in the third
most commonly observed combination of transitions and
included 534 individuals with AD. The primary diagnoses
were AD in the index home or outpatient setting, pneumo-
nia in the inpatient setting, and hypertension in the SNF
(Supplementary Figure S3).
Inpatient Setting fiHome or Outpatient Setting fiInpatient
Setting
The fourth combination included 301 participants who
transitioned from an inpatient to a home or outpatient
and back to an inpatient setting. The primary discharge
diagnosis in the index inpatient setting was syncope and
collapse, diabetes mellitus in the home or outpatient set-
ting, and chest pain in the second inpatient setting (Sup-
plementary Figure S4).
Cost Associated with Commonly Observed
Combinations of Transitions
Home or Outpatient Setting fiInpatient Settingfi Home/
Outpatient Setting
The average total Medicare expenditures of the first com-
bination was $29,550 over 6 months. The average LOS
was 74 days in the first home or outpatient setting, which
accounted for 14.6% ($4,322) of the average total cost.
The next transition was to an inpatient setting, where par-
ticipants remained an average of 6 days, accounting for
31.3% ($9,250) of the total cost. The average length of
Figure 2. Transition from (A) inpatient, (B) home or outpatient.
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stay for the second time in the home or outpatient setting
to the end of the 6 months after the AD diagnosis or next
transition (if any) was 78 days, and participants incurred
an average of $4,472 (15.1%) of the average total cost
during the 6-month postdiagnosis period (Supplementary
Figure S1).
Inpatient Setting fiSNF Settingfi Home or Outpatient
Setting
Average total healthcare expenditures were $51,145 dur-
ing the 6 months after AD diagnosis for participants in
the second combination of transitions. These participants
were hospitalized for an average of 8 days and incurred
24.8% ($12,699) of the average total cost. Participants
remained for an average of 43 days during their SNF stay,
accounting for 39.9% ($20,417) of the average total cost.
The mean LOS for the home or outpatient setting to the
end of the 6 months after AD diagnosis or next transition
(if any) was 102 days, and participants incurred 9.7%
($4,985) of the average total cost (Supplementary Figure
S2).
Home or Outpatient Setting fiInpatient Settingfi SNF
Setting
The average total Medicare expenditure of the third com-
bination was $52,183 over 6 months after AD diagnosis.
The mean LOS in the index home or outpatient setting
was 65 days, which accounted for 6.3% ($3,296) of the
average total cost before being admitted to the hospital.
The average hospital stay was 8 days, which cost 25%
($13,263) of the average total cost. These individuals were
later discharged to a SNF, where they remained for an
average of 60 days, incurring an average of 32.9%
($17,185) of the average total cost in the 6-month period
(Supplementary Figure S3).
Inpatient Setting fiHome or Outpatient Setting fiInpatient
Setting
Individuals in the fourth combination incurred an average
$50,780 of costs during the 6 months after AD diagnosis.
These individuals were hospitalized for an average of 8
days, resulting in an average cost of $11,283 (22.2% of
the average total cost). Participants remained for an
Figure 3. Transition from (A) skilled nursing facility, (B) hospice setting.
868 KHANDKER ET AL. MAY 2018–VOL. 66, NO. 5 JAGS
average of 65 days in the home or outpatient setting
before being re-admitted to the hospital, where they
remained for an average of 6 days. The mean cost in the
home or outpatient setting was $4,043, which was
approximately 8% of the average total cost; the average
cost of the second inpatient setting was $11,124 (21.1%
of the average total cost) (Supplementary Figure S4).
DISCUSSION
A significant portion of individuals received their first AD
diagnosis in a nonambulatory setting—particularly inpa-
tient settings. Participants diagnosed in nonambulatory
settings went through more transitions of care during the
6-month postdiagnosis period than those who were diag-
nosed in a home or outpatient settings. Overall economic
burden was substantial for participants diagnosed in non-
ambulatory settings—an average of $41,468 (results not
shown) during the 6 months after AD diagnosis—whereas
participants diagnosed in an ambulatory setting incurred
an average of only $12,597 during the same period.
The 30-day readmission rate after index hospitaliza-
tion discharge was 22% in this analysis. In addition, the
current study results indicate that, once an AD diagnosis
is made, especially if a diagnosis is made in an inpatient
setting, subsequent care is necessary. It is possible that
these individuals were not adequately managed or were
not given an adequate management postdischarge plan,
which might have resulted in a high readmission rate. Fur-
thermore, individuals with AD with other comorbidities
need to be properly managed and treated for all of their
conditions to prevent some of the extensive additional
care. The cost of comorbid conditions in individuals with
AD could explain some of the cost differences between
index settings and transitions between settings. We did not
evaluate the effect of the costs of comorbidities in the cur-
rent analysis because it was beyond of the scope of the
study.
Early detection of dementia is helpful in delivering
appropriate care and offering direct benefits to individuals
with dementia,11 and studies of hospital data have found
that early detection of AD can be cost-saving.12–14 The
observed benefit from the study findings suggests that par-
ticipants managed in home and outpatient settings who
did not have another transition during the 6-month post-
diagnosis period, were better managed and cost the health-
care system less. This highlights the need to reevaluate
management of AD by preventing frequent hospitaliza-
tions with proactive outpatient care15 because the earlier
an individual is managed, the longer he or she can avoid
intensive healthcare resource encounters.
We also observed high cost burden for participants
who transitioned to institutional care facilities, such as an
inpatient setting or SNF, or those who transitioned twice to
an inpatient setting. As reported above, AD was not listed
as an admitting diagnosis for most of these individuals.
Even when transitions from care settings where AD was ini-
tially diagnosed were assessed, AD was not observed to be
the primary diagnosis for subsequent care settings. Further-
more, AD exacerbates other comorbid conditions, and indi-
viduals with AD tend not to adhere to management because
of their cognitive impairment, which can complicate their
care.16,17 Our study was exploratory and descriptive and
provides a preliminary examination of how these comorbid-
ities are present among AD patients across different health-
care settings. Dementia, even if it is not the primary reason
for an episode of care, can have a profound effect on care
delivery and outcomes18–20
The health status of an individual seeking care for an
acute event such as hip fracture can be updated at the
onset of care for the acute episode and during transitions
to different care settings. A different approach might be
developed for individuals seeking care for a chronic illness
such as AD. Being a chronic disease, AD is difficult to
study in terms of episodes of care because it is often diffi-
cult to define a start and end of an episode for a chronic
disease. Even though our health economic approach to
episodes might not easily transition into a bundled pay-
ment approach, they can help analyze transitions of care
between healthcare settings for individuals with AD.
Although claims data are valuable for the effective
assessment of real-world health information, there are
inherent limitations in this study. The main challenge of
existing bundles is their short duration because most cover
services up to 90 days after hospital discharge for Medi-
care beneficiaries.21 Further studies should evaluate
bundled payment using longer follow-up time frames if
they are to be useful for chronic diseases. In most institu-
tional settings, AD was not coded as an admitting diagno-
sis in the current analysis. Undercoding of AD in acute
hospital and outpatient care settings could cause this, as
previously discussed.22 Measures such as AD duration, dis-
ease severity and progression, stage of disease, cause of
death, health behaviors, and caregiver information were
lacking in the Medicare data, so study participants may
represent individuals across the spectrum of dementia
severity and may not reflect results for individuals with
new onset of AD. This study was descriptive, so factors
such as age, sex, and comorbid conditions that could
affect individuals’ costs and transitions of care were not
adjusted in a multivariate model. Methodologically, a mul-
tivariate analysis of a sequence of acute events as part of
an overall episode is not straightforward because the pat-
tern of such care will vary according to the individual.
This study included fee-for-service beneficiaries enrolled in
Medicare Parts A and B, which may limit generalizability
of the study results to individuals enrolled in Medicare
Part C. Studies are needed to determine the significance of
the episode-of-care approach to analysis of the health eco-
nomics and quality of care in Medicare Part C settings. At
the time of this analysis, ICD-9 code 331.0 was a billable
code. It is likely that the switch from ICD-9 to ICD-10
codes for disease classification will improve results and
quality of care because ICD-10 codes are more specific to
individual disease conditions, allowing for more effective
disease management.
This analysis displays how an episode-of-care
approach might be implemented using health economic
data to identify individuals at risk of hospitalization and
analyze care across the continuum of care for individuals
with AD. This study highlights the number of transitions,
time between each transition, and healthcare expenditures
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across different healthcare facilities for individuals newly
diagnosed with AD, which could help stakeholders and
medical professionals to better manage individuals with
AD in different healthcare settings and guide future
research.
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